-Peter L Choyke Researcher Activity Profile

Research Author Detailed Information 

Peter L Choyke Publication Rate By Year

Peter L Choyke has published 1 paper(s) in 1982, 1 paper(s) in 1984, 1 paper(s) in 1985, 1 paper(s) in 1987, 1 paper(s) in 1989, 1 paper(s) in 1990, 2 paper(s) in 1992, 1 paper(s) in 1994, 1 paper(s) in 1996, 1 paper(s) in 1998, 3 paper(s) in 2001, 2 paper(s) in 2006, 31 paper(s) in 2007, 1 paper(s) in 2008, for a total of 48 research publications in total.

Peter L Pl Choyke Author Information

LAST NAME: choyke

FIRST NAME: Peter L

INITIALS: pl

AFFILIATION:

Papers

Peter L Choyke's Publication Record

1. A comparison of the emission efficiency of four common green fluorescence dyes after internalization into cancer cells. Year Published: 2006
Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892-1088, USA.
2. Spectral near-infrared fluorescence imaging of curved surfaces using projection reconstruction algorithms. Year Published: 2007
Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892-1088, USA.
3. Ascorbate in pharmacologic concentrations selectively generates ascorbate radical and hydrogen peroxide in extracellular fluid in vivo. Year Published: 2007
Molecular and Clinical Nutrition Section, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
4. Toward improved syntheses of dendrimer-based magnetic resonance imaging contrast agents: new bifunctional diethylenetriaminepentaacetic acid ligands and nonaqueous conjugation chemistry. Year Published: 2007
Radiation Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 10 Center Drive, Bethesda, Maryland 20892-1088, USA.
5. Dynamic contrast-enhanced MRI of prostate cancer at 3 T: a study of pharmacokinetic parameters. Year Published: 2007
Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA.
6. Targeted optical fluorescence imaging of human ovarian adenocarcinoma using a galactosyl serum albumin-conjugated fluorophore. Year Published: 2007
Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, NIH, 10 Center Drive, Bethesda, MD 20892-1088, USA.
7. Is it possible to quantify fluorescence during optical endoscopy? Year Published: 2007
Molecular Imaging Program, National Cancer Institute, Bethesda, MD 20892-1088, USA. pchoyke@nih.gov
8. A Self-Quenched Galactosamine-Serum Albumin-RhodamineX Conjugate: A "Smart" Fluorescent Molecular Imaging Probe Synthesized with Clinically Applicable Material for Detecting Peritoneal Ovarian Cancer Metastases. Year Published: 2007
Authors' Affiliations: Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland and Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan.
9. Tumor-targeted optical imaging in the management of peritoneal carcinomatosis. Year Published: 2007
Sanford School of Medicine, The University of South Dakota, USA.
10. D-galactose receptor-targeted in vivo spectral fluorescence imaging of peritoneal metastasis using galactosamin-conjugated serum albumin-rhodamine green. Year Published: 2007
National Institutes of Health, National Cancer Institute, Center for Cancer Research, Molecular Imaging Program, Bethesda, Maryland 20892-1088.
11. Simultaneous integrated boost of biopsy proven, MRI defined dominant intra-prostatic lesions to 95 Gray with IMRT: early results of a phase I NCI study. Year Published: 2007
Department of Radiation Medicine, Roswell Park Cancer Institute, Buffalo, USA. singhanu@yahoo.com.
12. D-galactose receptor-targeted in vivo spectral fluorescence imaging of peritoneal metastasis using galactosamin-conjugated serum albumin-rhodamine green. Year Published: 2007
National Institutes of Health, National Cancer Institute, Center for Cancer Research, Molecular Imaging Program, Bethesda, Maryland 20892-1088, USA.
13. In vivo diagnosis of epidermal growth factor receptor expression using molecular imaging with a cocktail of optically labeled monoclonal antibodies. Year Published: 2007
Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
14. Spectral near-infrared fluorescence imaging of curved surfaces using projection reconstruction algorithms. Year Published: 2007
Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892-1088, USA.
15. Tumor-targeted optical imaging in the management of peritoneal carcinomatosis. Year Published: 2007
Sanford School of Medicine, The University of South Dakota, USA.
16. Simultaneous integrated boost of biopsy proven, MRI defined dominant intra-prostatic lesions to 95 Gray with IMRT: early results of a phase I NCI study. Year Published: 2007
Department of Radiation Medicine, Roswell Park Cancer Institute, Buffalo, USA. singhanu@yahoo.com
17. Clinical, genetic and radiographic analysis of 108 patients with von Hippel-Lindau disease (VHL) manifested by pancreatic neuroendocrine neoplasms (PNETs). Year Published: 2007
Tumor Angiogenesis Section, Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, Md. 20892, USA.
18. Salvage partial nephrectomy for hereditary renal cancer: feasibility and outcomes. Year Published: 2007
Urologic Oncology Branch and Molecular Imaging Program (PLC), Center for Cancer Research, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland.
19. Targeted optical fluorescence imaging of human ovarian adenocarcinoma using a galactosyl serum albumin-conjugated fluorophore. Year Published: 2007
Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, NIH, 10 Center Drive, Bethesda, MD 20892-1088, USA.
20. Salvage partial nephrectomy for hereditary renal cancer: feasibility and outcomes. Year Published: 2007
Urologic Oncology Branch and Molecular Imaging Program (PLC), Center for Cancer Research, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland 20892-1107, USA. bratslag@mail.nih.gov
21. A self-quenched galactosamine-serum albumin-rhodamineX conjugate: a "smart" fluorescent molecular imaging probe synthesized with clinically applicable material for detecting peritoneal ovarian cancer metastases. Year Published: 2007
Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892-1088, USA.
22. In Vivo Molecular Imaging to Diagnose and Subtype Tumors through Receptor-Targeted Optically Labeled Monoclonal Antibodies. Year Published: 2007
Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Building 10, Room 1B40, Bethesda, MD, 20892-1088, USA.
23. In vivo molecular imaging to diagnose and subtype tumors through receptor-targeted optically labeled monoclonal antibodies. Year Published: 2007
Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Building 10, Room 1B40, Bethesda, MD, 20892-1088, USA.
24. In vivo diagnosis of epidermal growth factor receptor expression using molecular imaging with a cocktail of optically labeled monoclonal antibodies. Year Published: 2007
Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
25. Percutaneous radio frequency ablation of small renal tumors: initial results. Year Published: 2001
Urologic Oncology Branch, National Cancer Institute and Division of Radiology, Warren G. Magnuson Clinical Center, National Institutes of Health, Bethesda, Maryland.
26. Clinical, genetic and radiographic analysis of 108 patients with von Hippel-Lindau disease (VHL) manifested by pancreatic neuroendocrine neoplasms (PNETs). Year Published: 2007
Tumor Angiogenesis Section, Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, Md. 20892, USA.
27. Spectral near-infrared fluorescence imaging of curved surfaces using projection reconstruction algorithms. Year Published: 2007
Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892-1088, USA.
28. D-galactose receptor-targeted in vivo spectral fluorescence imaging of peritoneal metastasis using galactosamin-conjugated serum albumin-rhodamine green. Year Published: 2007
National Institutes of Health, National Cancer Institute, Center for Cancer Research, Molecular Imaging Program, Bethesda, Maryland 20892-1088, USA.
29. A self-quenched galactosamine-serum albumin-rhodamineX conjugate: a "smart" fluorescent molecular imaging probe synthesized with clinically applicable material for detecting peritoneal ovarian cancer metastases. Year Published: 2007
Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892-1088, USA.
30. Salvage partial nephrectomy for hereditary renal cancer: feasibility and outcomes. Year Published: 2007
Urologic Oncology Branch and Molecular Imaging Program (PLC), Center for Cancer Research, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland 20892-1107, USA. bratslag@mail.nih.gov
31. In vivo diagnosis of epidermal growth factor receptor expression using molecular imaging with a cocktail of optically labeled monoclonal antibodies. Year Published: 2007
Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
32. Clinical, genetic and radiographic analysis of 108 patients with von Hippel-Lindau disease (VHL) manifested by pancreatic neuroendocrine neoplasms (PNETs). Year Published: 2007
Tumor Angiogenesis Section, Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, Md. 20892, USA.
33. Prostate cancer: what is the future role for imaging? Year Published: 2001
Division of Urology, Department of Surgery, University of North Carolina at Chapel Hill, 427 Burnett-Womack Bldg., CB 7235, Chapel Hill, NC 27599-7235, USA.
34. Hepatic MR angiography: a multiobserver comparison of visualization methods. Year Published: 2001
Diagnostic Radiology Department, The Clinical Center, National Institutes of Health, Bldg. 10, Rm. 1C660, Bethesda, MD 20892-1182, USA.
35. Mycotic pulmonary artery aneurysm: complication of Aspergillus endocarditis. Year Published: 1982
36. Nongated cardiac magnetic resonance imaging: preliminary experience at 0.12 T. Year Published: 1984
37. The clinical and imaging spectrum of pancreaticoduodenal lymph node enlargement. Year Published: 1985
38. Thymic atrophy and regrowth in response to chemotherapy: CT evaluation. Year Published: 1987
39. CT evaluation of suspected hepatic metastases: comparison of techniques for i.v. contrast enhancement. Year Published: 1989
Department of Radiology, Georgetown University Hospital, Washington, DC 20007-2197.
40. Diagnostic evaluation of cancer patients with pelvic pain: comparison of scintigraphy, CT, and MR imaging. Year Published: 1990
Radiation Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892.
41. Stress-induced adrenal hyperplasia simulating metastatic disease: CT and MR findings. Year Published: 1992
42. The natural history of renal lesions in von Hippel-Lindau disease: a serial CT study in 28 patients. Year Published: 1992
Department of Radiology, Warren G. Magnuson Clinical Center, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892.
43. Large-cell calcifying Sertoli cell tumor of the testis: appearance at sonography. Year Published: 1994
University of North Dakota School of Medicine, Mandan 58554.
44. Morphing radiologic images: applications on a desktop computer. Year Published: 1996
Department of Radiology, National Institutes of Health, Warren G. Magnuson Clinical Center, Bethesda, MD 20892-1182, USA.
45. Nonmalignant renal disease in pediatric patients with Beckwith-Wiedemann syndrome. Year Published: 1998
Department of Radiology, Clinical Center, National Institutes of Health, Bethesda, MD 20892, USA.
46. CT and MRI of hepatic abscess in patients with chronic granulomatous disease. Year Published: 2006
Molecular Imaging Program, National Cancer Institute, Bldg. 10, Rm. B3B69, 9000 Rockville Pike, Bethesda, MD 20892, USA.
47. Dynamic contrast-enhanced MRI of prostate cancer at 3 T: a study of pharmacokinetic parameters. Year Published: 2007
Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA.
48. Initial clinical experience with real-time transrectal ultrasonography-magnetic resonance imaging fusion-guided prostate biopsy. Year Published: 2008
Radiation Medicine Department, Roswell Park Cancer Institute, Buffalo, NY 14263, USA. anurag.singh@roswellpark.org